Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Jose L Batista , Tracy Makuvire , Jonathan D Davis , et al Added: 1 week ago

Cardiovascular Renal Metabolic

Heart Failure
SGLTi and GLP-1 in HF
Author(s): Jose L Batista , Tracy Makuvire , Jonathan D Davis , et al Added: 10 months ago

Cardiovascular Renal Metabolic

Heart Failure
Enlicitide: Oral PCSK9 Inhibitor Lowers LDL-C by 56%
Added: 2 weeks ago Source:  Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 4 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Renal Metabolic
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 2 years ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
Early SGLT2i/MRA Use Benefits Suspected HF Patients
Added: 1 week ago Source:  Cardiac Failure Review Journal
Delays in diagnosis and treatment for patients with suspected heart failure (HF) in the community can lead to preventable hospitalisations and deaths. A new modelling study by Dr Kieran Docherty and colleagues suggests that early initiation of disease-modifying therapies in select patients at the time of an elevated natriuretic peptide test could significantly reduce these adverse outcomes… View more

Intervention

Heart Failure
AHA 24: The EMPEROR-Preserved Trial
Author(s): Andrew JS Coats Added: 1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR… View more

Heart Failure
NA Mark Estes III
Research Area(s) / Expertise:

Electrophysiology & Arrhythmia

 Job title: Professor of Medicine & Director
Dr NA Mark Estes III is an accomplished Professor of Medicine at the University of Pittsburgh and Director of the Clinical Cardiac Electrophysiology Fellows Program at the Heart and Vascular Institute at UPMC. He graduated from the University of Pennsylvania with an undergraduate degree and was elected to AOA at the University of Cincinnati College of Medicine. Dr. Estes completed his medical… View more